Adverse events144

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 144

Type	Event	Organ system	Group	Affected	At risk
other	Diarrhoea	Gastrointestinal disorders	Total Open-label Experience	20	2,579
other	Diarrhoea	Gastrointestinal disorders	Double-blind Retreatment Experience - Rifaximin Group	7	328
other	Diarrhoea	Gastrointestinal disorders	Double-blind Retreatment Experience - Placebo Group	3	308
other	Nausea	Gastrointestinal disorders	Total Open-label Experience	52	2,579
other	Nausea	Gastrointestinal disorders	Double-blind Retreatment Experience - Rifaximin Group	12	328
other	Nausea	Gastrointestinal disorders	Double-blind Retreatment Experience - Placebo Group	7	308
other	Vomiting	Gastrointestinal disorders	Total Open-label Experience	24	2,579
other	Vomiting	Gastrointestinal disorders	Double-blind Retreatment Experience - Rifaximin Group	2	328
other	Vomiting	Gastrointestinal disorders	Double-blind Retreatment Experience - Placebo Group	5	308
other	Bronchitis	Infections and infestations	Total Open-label Experience	15	2,579
other	Bronchitis	Infections and infestations	Double-blind Retreatment Experience - Rifaximin Group	9	328
other	Bronchitis	Infections and infestations	Double-blind Retreatment Experience - Placebo Group	5	308
other	Nasopharyngitis	Infections and infestations	Total Open-label Experience	36	2,579
other	Nasopharyngitis	Infections and infestations	Double-blind Retreatment Experience - Rifaximin Group	10	328
other	Nasopharyngitis	Infections and infestations	Double-blind Retreatment Experience - Placebo Group	9	308
other	Influenza	Infections and infestations	Total Open-label Experience	33	2,579
other	Influenza	Infections and infestations	Double-blind Retreatment Experience - Rifaximin Group	7	328
other	Influenza	Infections and infestations	Double-blind Retreatment Experience - Placebo Group	2	308
other	Sinusitis	Infections and infestations	Total Open-label Experience	34	2,579
other	Sinusitis	Infections and infestations	Double-blind Retreatment Experience - Rifaximin Group	7	328

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01543178/events

API reference For AI assistants

Adverse events144

Sources 3

Read this list from software.